CS
VKTX icon

Credit Suisse’s Viking Therapeutics VKTX Stock Holding History

Credit Suisse’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$7.36M Buy
89,793
+1,505
+2% +$67K 0.01% 1073
2023
Q4 		$1.64M Sell
88,288
-7,526
-8% -$98.4K ﹤0.01% 2014
2023
Q3 		$1.06M Sell
95,814
-17,610
-16% -$252K ﹤0.01% 2264
2023
Q2 		$1.84M Buy
113,424
+59,847
+112% +$1.25M ﹤0.01% 1968
2023
Q1 		$892K Buy
+53,577
New +$553K ﹤0.01% 2401
2022
Q3 		– Sell
-36
Closed – – 4317
2022
Q2 		$0 Sell
36
-49,098
-100% -$122K ﹤0.01% 4348
2022
Q1 		$148K Sell
49,134
-1,228
-2% -$4.41K ﹤0.01% 3437
2021
Q4 		$231K Buy
50,362
+5,992
+14% +$33.6K ﹤0.01% 4224
2021
Q3 		$279K Buy
44,370
+4,783
+12% +$29.5K ﹤0.01% 4112
2021
Q2 		$237K Sell
39,587
-25,566
-39% -$152K ﹤0.01% 4209
2021
Q1 		$413K Sell
65,153
-85,770
-57% -$603K ﹤0.01% 3879
2020
Q4 		$849K Sell
150,923
-66,109
-30% -$400K ﹤0.01% 3443
2020
Q3 		$1.26M Buy
217,032
+29,123
+15% +$201K ﹤0.01% 2757
2020
Q2 		$1.35M Buy
187,909
+62,690
+50% +$416K ﹤0.01% 2691
2020
Q1 		$585K Sell
125,219
-14,477
-10% -$89K ﹤0.01% 3014
2019
Q4 		$1.12M Buy
139,696
+100,356
+255% +$732K ﹤0.01% 3040
2019
Q3 		$270K Buy
39,340
+4,869
+14% +$36.2K ﹤0.01% 3744
2019
Q2 		$286K Sell
34,471
-3,554
-9% -$30.4K ﹤0.01% 3703
2019
Q1 		$378K Buy
38,025
+7,660
+25% +$64.1K ﹤0.01% 3485
2018
Q4 		$233K Buy
+30,365
New +$363K ﹤0.01% 3617
2018
Q3 		– Sell
-86,488
Closed -$821K – 4000
2018
Q2 		$821K Buy
+86,488
New +$575K ﹤0.01% 3153

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Credit Suisse's VKTX Position: Q1 2024 in Review

Credit Suisse increased its Viking Therapeutics (VKTX) stake by 1.7% in Q1 2024, buying an estimated $67K and bringing the position to 89,793 shares worth $7.36M. The position accounts for 0.01% of the portfolio, ranked #1073.

Credit Suisse first reported a position in VKTX in Q2 2018 and has held it in 21 quarters since. 375 funds tracked by Wall St. Rank hold VKTX as of Q1 2024.

  • Credit Suisse held 89,793 shares of Viking Therapeutics worth $7.36M as of Q1 2024.
  • Credit Suisse bought 1,505 Viking Therapeutics shares in Q1 2024, an estimated $67K.
  • Viking Therapeutics made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #1073 holding.
  • Credit Suisse first reported a position in Viking Therapeutics in Q2 2018 and has held it in 21 quarters since.
  • 375 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.